| Nov 19 |
ABEO: FDA Accepts BLA Re-Submission for Pz-cel; PDUFA Date of April 29, 2025; Raising Valuation to $9.50…
|
| Nov 15 |
Abeona Therapeutics Inc (ABEO) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...
|
| Nov 14 |
Abeona Therapeutics: Q3 Earnings Snapshot
|
| Nov 14 |
Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
|
| Nov 12 |
Abeona Therapeutics gets PDUFA date for its epidermolysis bullosa treatment
|
| Nov 12 |
Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
|
| Nov 4 |
Abeona Therapeutics® Announces Participation in November Investor Conferences
|
| Oct 29 |
Abeona Therapeutics resubmits biologics license application for pz-cel to FDA
|
| Oct 29 |
Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration
|
| Oct 9 |
Abeona Therapeutics Inc (ABEO) Q2 2024 Earnings Call Highlights: Strong Financial Performance ...
|
